Hosted on MSN1mon
GSK raises long-term guidance, announces buybacks
The company ... GSK’s (NYSE:GSK) new vaccine for respiratory syncytial virus (RSV) and Shingrix, its shingles vaccine, fell ~69% YoY and ~4% YoY. Meanwhile, GSK’s (NYSE:GSK) full-year revenue ...
Yahoo Finance28d
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend
Accordingly, GSK investors that purchase the stock on or after the 20th of February will not receive the dividend, which will be paid on the 10th of April. The company's next dividend payment will ...
Morningstar26d
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
Please consult the full Prescribing Information for additional safety information GSK is a global biopharma company with a purpose ... in GSK’s Annual Report on Form 20-F for 2023, and GSK ...
Pharmabiz18d
GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.
GSK plc announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing ... GIST represent the most prevalent ...